Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 11-Aug-23 4:48 PM View:  | Gowen Maxine Director | Idera Pharmaceuticals, Inc. (ACGN) | 10-Aug-23 | Sale | 51 | $0.51 | $26.01 | (100%) 51 to 0 | |
| 11-Aug-23 4:30 PM View: | Milano Vincent Director | Idera Pharmaceuticals, Inc. (ACGN) | 10-Aug-23 | Sale | 3,283 | $0.53 | $1,750.17 | (27%) 12.27K to 8.99K | |
| 19-Jul-23 4:05 PM View: | Pillar Invest Corp 10% Owner | Idera Pharmaceuticals, Inc. (ACGN) | 13-Jul-23 | Sale | 2,213 | $1.54 | $3,408.02 | (< 1%) 659.44K to 657.23K | |
| 19-Jul-23 4:05 PM View: | Pillar Invest Corp 10% Owner | Idera Pharmaceuticals, Inc. (ACGN) | 12-Jul-23 | Private Sale | 3,605 | $1.58 | $5,695.90 | (< 1%) 663.05K to 659.44K | |
| 19-Jul-23 4:05 PM View: | Pillar Invest Corp 10% Owner | Idera Pharmaceuticals, Inc. (ACGN) | 17-May-23 | Purchase | 26,965 | $1.42 | $38,290.30 | 4% 636.08K to 663.05K | |
| 18-May-23 2:38 PM View: | Chopra Atul 10% Owner | Idera Pharmaceuticals, Inc. (ACGN) | 17-May-23 | Sale | 24,800 | $1.33 | $33,103.80 | (2%) 1.23M to 1.21M | |
| 18-May-23 2:38 PM View: | Chopra Atul 10% Owner | Idera Pharmaceuticals, Inc. (ACGN) | 16-May-23 | Sale | 32,436 | $1.42 | $45,972.10 | (3%) 1.26M to 1.23M | |
| 18-May-23 2:38 PM View: | Chopra Atul 10% Owner | Idera Pharmaceuticals, Inc. (ACGN) | 15-May-23 | Private Sale | 78,436 | $1.48 | $116,371.00 | (6%) 1.34M to 1.26M | |
| 18-May-23 2:35 PM View: | Chopra Atul 10% Owner | Idera Pharmaceuticals, Inc. (ACGN) | 12-May-23 | Private Sale | 81,486 | $1.56 | $126,947.00 | (6%) 1.42M to 1.34M | |
| 18-May-23 2:34 PM View: | Chopra Atul 10% Owner | Idera Pharmaceuticals, Inc. (ACGN) | 11-May-23 | Private Sale | 47,166 | $1.84 | $86,924.40 | (3%) 1.47M to 1.42M | |
| 19-Jan-23 9:47 PM View: | Jordan Andrew R Chief Strategy Officer | Idera Pharmaceuticals, Inc. (ACGN) | 17-Jan-23 | Option Exercise | 402,529 | -- | -- | 815% 49.36K to 451.89K | |
| 19-Jan-23 9:45 PM View: | Taylor John Clayton Chief Executive Officer Director | Idera Pharmaceuticals, Inc. (ACGN) | 17-Jan-23 | Option Exercise | 1,341,760 | -- | -- | 1051% 127.72K to 1.47M | |
| 19-Jan-23 9:46 PM View: | Salain Daniel Chief Operating Officer | Idera Pharmaceuticals, Inc. (ACGN) | 17-Jan-23 | Option Exercise | 1,341,760 | -- | -- | 1051% 127.72K to 1.47M | |
| 12-Jan-23 8:00 PM View: | Dougherty Michael R Director | Idera Pharmaceuticals, Inc. (ACGN) | 11-Jan-23 | Grant | 33,523 | $0.44 | $14,750.10 | 10% 341.63K to 375.15K | |
| 10-Jan-23 9:15 PM View: | Kirby John J. Chief Financial Officer | Idera Pharmaceuticals, Inc. (ACGN) | 06-Jan-23 | Payment of Exercise | 119,957 | $0.71 | $85,157.50 | (27%) 436.85K to 316.89K | |
| 10-Jan-23 9:17 PM View: | Lim Bryant David SVP and General Counsel | Idera Pharmaceuticals, Inc. (ACGN) | 06-Jan-23 | Payment of Exercise | 119,957 | $0.71 | $85,157.50 | (28%) 429.65K to 309.69K | |
| 10-Jan-23 9:19 PM View: | Jordan Andrew R Chief Strategy Officer | Idera Pharmaceuticals, Inc. (ACGN) | 06-Jan-23 | Grant | 261,718 | -- | -- | 40% 651.36K to 913.08K | |
| 10-Jan-23 9:15 PM View: | Kirby John J. Chief Financial Officer | Idera Pharmaceuticals, Inc. (ACGN) | 06-Jan-23 | Grant | 399,218 | -- | -- | 1061% 37.63K to 436.85K | |
| 10-Jan-23 9:19 PM View: | Jordan Andrew R Chief Strategy Officer | Idera Pharmaceuticals, Inc. (ACGN) | 06-Jan-23 | Payment of Exercise | 73,940 | $0.71 | $52,490.00 | (8%) 913.08K to 839.14K | |
| 10-Jan-23 9:17 PM View: | Lim Bryant David SVP and General Counsel | Idera Pharmaceuticals, Inc. (ACGN) | 06-Jan-23 | Grant | 399,218 | -- | -- | 1312% 30.43K to 429.65K | |
| 05-Oct-22 9:26 PM View: | Dougherty Michael R Director | Idera Pharmaceuticals, Inc. (ACGN) | 03-Oct-22 | Grant | 58,516 | $0.37 | $21,937.60 | 21% 283.12K to 341.63K | |
| 30-Sep-22 9:48 PM View: | Jordan Andrew R Chief Strategy Officer | Idera Pharmaceuticals, Inc. (ACGN) | 28-Sep-22 | Grant | 651,364 | -- | -- | 100% 0 to 651.36K | |
| 30-Sep-22 9:49 PM View: | Taylor John Clayton Chief Executive Officer Director | Idera Pharmaceuticals, Inc. (ACGN) | 28-Sep-22 | Grant | 2,171,210 | -- | -- | 100% 0 to 2.17M | |
| 03-Oct-22 6:06 PM View: | Novaquest Co-Investment Fun... Director | Idera Pharmaceuticals, Inc. (ACGN) | 28-Sep-22 | Acquisition (other) | 5 | -- | -- | 100% 0 to 5 | |
| 30-Sep-22 9:49 PM View: | Salain Daniel Chief Operating Officer | Idera Pharmaceuticals, Inc. (ACGN) | 28-Sep-22 | Grant | 2,171,210 | -- | -- | 100% 0 to 2.17M | |
| 30-Sep-22 9:50 PM View: | Wooten Ronald J Director | Idera Pharmaceuticals, Inc. (ACGN) | 28-Sep-22 | Acquisition (other) Duplicate | 5 | -- | -- | 100% 0 to 5 | |
| 26-Sep-22 4:32 PM View: | Pillar Invest Corp 10% Owner | Idera Pharmaceuticals, Inc. (ACGN) | 22-Sep-22 | Exercise (in-the money or at-the-money) | 1,533,160 | $0.01 | $15,331.60 | 18% 8.45M to 9.98M | |
| 06-Jul-22 4:30 PM View: | Dougherty Michael R Director | Idera Pharmaceuticals, Inc. (ACGN) | 01-Jul-22 | Grant | 50,086 | $0.44 | $21,937.70 | 21% 233.03K to 283.12K | |
| 05-Apr-22 5:04 PM View: | Dougherty Michael R Director | Idera Pharmaceuticals, Inc. (ACGN) | 01-Apr-22 | Grant | 41,155 | $0.54 | $22,017.90 | 21% 191.88K to 233.03K | |
| 05-Jan-22 5:00 PM View: | Dougherty Michael R Director | Idera Pharmaceuticals, Inc. (ACGN) | 03-Jan-22 | Grant | 37,062 | $0.59 | $21,866.60 | 24% 154.81K to 191.88K | 4% |
| 21-Dec-21 4:16 PM View: | Kirby John J. Chief Financial Officer | Idera Pharmaceuticals, Inc. (ACGN) | 17-Dec-21 | Market Purchase | 10,000 | $0.62 | $6,150.00 | 36% 27.63K to 37.63K | (5%) |
| 04-Oct-21 8:43 PM View: | Dougherty Michael R Director | Idera Pharmaceuticals, Inc. (ACGN) | 04-Oct-21 | Grant | 21,229 | $1.03 | $21,865.90 | 16% 133.58K to 154.81K | 0% |
| 21-Jun-21 4:10 PM View: | Soland Daniel B Chief Operating Officer | Idera Pharmaceuticals, Inc. (ACGN) | 18-Jun-21 | Market Purchase | 50,000 | $1.19 | $59,500.00 | 173% 28.84K to 78.84K | (3%) |
| 03-Jun-21 4:10 PM View: | Dougherty Michael R Director | Idera Pharmaceuticals, Inc. (ACGN) | 01-Jun-21 | Market Purchase | 85,000 | $1.19 | $101,150.00 | 175% 48.58K to 133.58K | (3%) |
| 05-Apr-21 4:30 PM View: | Goldberg Mark Alan Director | Idera Pharmaceuticals, Inc. (ACGN) | 01-Apr-21 | Grant | 10,511 | $1.32 | $13,874.50 | 28% 38.1K to 48.61K | (13%) |
| 05-Apr-21 4:30 PM View: | Geraghty James A Director | Idera Pharmaceuticals, Inc. (ACGN) | 01-Apr-21 | Grant | 14,773 | $1.32 | $19,500.40 | 14% 104.77K to 119.54K | (13%) |
| 05-Apr-21 4:30 PM View: | Schafer Carol Director | Idera Pharmaceuticals, Inc. (ACGN) | 01-Apr-21 | Grant | 11,177 | $1.32 | $14,753.60 | 23% 48.49K to 59.66K | (13%) |
| 05-Apr-21 4:30 PM View: | Dougherty Michael R Director | Idera Pharmaceuticals, Inc. (ACGN) | 01-Apr-21 | Grant | 10,939 | $1.32 | $14,439.50 | 29% 37.65K to 48.58K | (13%) |
| 31-Mar-21 9:51 PM View: | Pillar Invest Corp 10% Owner | Idera Pharmaceuticals, Inc. (ACGN) | 26-Mar-21 | Exercise (in-the money or at-the-money) | 2,495,810 | $0.01 | $24,958.10 | 18% 13.8M to 16.3M | |
| 29-Mar-21 4:14 PM View: | Tarka Elizabeth Ann Chief Medical Officer | Idera Pharmaceuticals, Inc. (ACGN) | 25-Mar-21 | Market Sale | 5,018 | $1.35 | $6,777.81 | (27%) 18.25K to 13.24K | 15% |
| 29-Mar-21 4:05 PM View: | Kirby John J. Chief Financial Officer | Idera Pharmaceuticals, Inc. (ACGN) | 25-Mar-21 | Market Sale | 6,250 | $1.42 | $8,875.62 | (18%) 33.88K to 27.63K | 20% |
| 29-Mar-21 4:09 PM View: | Lim Bryant David SVP and General Counsel | Idera Pharmaceuticals, Inc. (ACGN) | 25-Mar-21 | Market Sale | 7,630 | $1.36 | $10,377.60 | (20%) 38.06K to 30.43K | 16% |
| 31-Mar-21 9:51 PM View: | Pillar Invest Corp 10% Owner | Idera Pharmaceuticals, Inc. (ACGN) | 18-Mar-21 | Private Sale | 1,699,760 | $1.80 | $3,057,030.00 | 14% 12.1M to 13.8M | |
| 05-Mar-21 5:55 PM View: | Soland Daniel B Chief Operating Officer | Idera Pharmaceuticals, Inc. (ACGN) | 05-Mar-21 | Market Purchase | 10,000 | $3.89 | $38,950.00 | 53% 18.84K to 28.84K | (71%) |
| 31-Mar-21 9:51 PM View: | Pillar Invest Corp 10% Owner | Idera Pharmaceuticals, Inc. (ACGN) | 20-Jan-21 | Exercise (in-the money or at-the-money) | 643,525 | $0.01 | $6,435.25 | 4% 14.86M to 15.5M | |
| 12-Jan-21 7:08 PM View: | Lim Bryant David SVP and General Counsel | Idera Pharmaceuticals, Inc. (ACGN) | 12-Jan-21 | Market Sale | 1,711 | $4.21 | $7,201.77 | (4%) 39.77K to 38.06K | 73% |
| 12-Jan-21 7:00 PM View: | Milano Vincent President & CEO Director | Idera Pharmaceuticals, Inc. (ACGN) | 12-Jan-21 | Market Sale | 3,210 | $4.20 | $13,474.30 | (2%) 211.82K to 208.61K | 73% |
| 12-Jan-21 7:10 PM View: | Tarka Elizabeth Ann Chief Medical Officer | Idera Pharmaceuticals, Inc. (ACGN) | 12-Jan-21 | Market Sale | 1,745 | $4.19 | $7,309.81 | (9%) 20.0K to 18.25K | 73% |
| 12-Jan-21 7:12 PM View: | Kirby John J. Chief Financial Officer | Idera Pharmaceuticals, Inc. (ACGN) | 12-Jan-21 | Market Sale | 1,693 | $4.22 | $7,151.74 | (5%) 35.58K to 33.88K | 73% |
| 11-Jan-21 8:09 PM View: | Milano Vincent President & CEO Director | Idera Pharmaceuticals, Inc. (ACGN) | 05-Jan-21 | Market Sale | 2,740 | $3.91 | $10,700.00 | (1%) 214.56K to 211.82K | 71% |
